Use of PRAME Immunostaining to Distinguish Melanoma in Situ From Lentigo Senilis by Olds, Hailey et al.
Wayne State University 
Medical Student Research Symposium School of Medicine 
January 2021 
Use of PRAME Immunostaining to Distinguish Melanoma in Situ 







Follow this and additional works at: https://digitalcommons.wayne.edu/som_srs 
 Part of the Dermatology Commons, Diagnosis Commons, Neoplasms Commons, and the Skin and 
Connective Tissue Diseases Commons 
Recommended Citation 
Olds, Hailey; Utz, Sarah; and Mehregan, Darius, "Use of PRAME Immunostaining to Distinguish Melanoma 
in Situ From Lentigo Senilis" (2021). Medical Student Research Symposium. 84. 
https://digitalcommons.wayne.edu/som_srs/84 
This Research Abstract is brought to you for free and open access by the School of Medicine at 
DigitalCommons@WayneState. It has been accepted for inclusion in Medical Student Research Symposium by an 
authorized administrator of DigitalCommons@WayneState. 
Title: ​Use of PRAME Immunostaining to Distinguish Melanoma in Situ From Lentigo Senilis 
Authors: ​Hailey Olds, BS​1​, Sarah Utz, MD​1​, Darius Mehregan, MD​1  
Affiliations: ​1​Wayne State University Department of Dermatology, Detroit, MI 
Key words: ​melanoma in situ; lentigo senilis; PRAME; immunohistochemistry  
 
Abstract:  
PRAME (PReferentially expressed Antigen in MElanoma) is an antigen that is expressed by 
malignant cells in melanoma, as well as other cancers such as breast carcinoma, renal cell 
carcinoma, and leukemia. PRAME immunohistochemistry has proved effective in identifying 
malignant melanocytes in melanoma lesions, but it is unclear if it may be used to distinguish 
melanoma from benign melanocytic conditions, such as lentigo senilis. In particular, melanoma 
in situ may be confused with lentigo senilis clinically and histologically, thus PRAME 
immunostaining is potentially useful for differentiating these two lesions. We evaluated 31 
samples of lentigo senilis, 26 of melanoma in situ, and 17 of sun-damaged skin with PRAME 
immunostain. We found that there is significantly greater PRAME expression in melanoma in 
situ compared to both lentigo senilis and sun-damaged skin. Although these benign skin lesions 
contain some cells that are immunoreactive for PRAME, these cells are sparse compared to the 
dense PRAME-positive cells in melanoma in situ. This suggests that PRAME immunostaining 
could be a clinically useful tool for distinguishing melanoma in situ from lentigo senilis. 
However, it should be combined with other data, such as clinical impression and histology with 
H&E stain, given the possibility for false positive results. 
 
